Eyenovia Stock Tumbles on Termination of Phase III Myopia Study [Yahoo! Finance]
Eyenovia, Inc. (EYEN)
Last eyenovia, inc. earnings: 3/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=254685&p=irol-irhome
Company Research
Source: Yahoo! Finance
MicroPine is EYEN's proprietary drug-device combination of low-dose atropine administered using the company's Optejet dispensing platform. The decision was taken after an independent Data Review Committee (DRC) determined that the phase III CHAPERONE study of MicroPine was unlikely to meet its primary endpoint of less than 0.5 diopter progression in visual acuity over three years. The DRC evaluated safety and efficacy data from 252 patients and found no significant difference in myopia progression between the two treatment groups (0.01% and 0.1% atropine ophthalmic metered spray) and placebo. However, all doses of the candidate and the placebo were well-tolerated in the CHAPERONE study, with only mild and infrequent adverse events. The complete study data is yet to be provided to Eyenovia. Based on this DRC feedback, Eyenovia has decided to terminate the phase III CHAPERONE study of MicroPine for the myopia indication. The company is currently gearing up for a thorough review of
Show less
Read more
Impact Snapshot
Event Time:
EYEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYEN alerts
High impacting Eyenovia, Inc. news events
Weekly update
A roundup of the hottest topics
EYEN
News
- Eyenovia, Inc. (NASDAQ: EYEN) had its "neutral" rating re-affirmed by analysts at LADENBURG THALM/SH SH.MarketBeat
- Eyenovia, Inc. (NASDAQ: EYEN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $12.00.MarketBeat
- Eyenovia stock plummets following Phase III myopia trial failure [Yahoo! Finance]Yahoo! Finance
- Eyenovia, Inc. (NASDAQ: EYEN) had its "hold" rating re-affirmed by analysts at Brookline Capital Management.MarketBeat
- Eyenovia, Inc. (NASDAQ: EYEN) had its "market perform" rating re-affirmed by analysts at William Blair.MarketBeat
EYEN
Earnings
- 11/12/24 - Beat
EYEN
Sec Filings
- 11/20/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- EYEN's page on the SEC website